Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

Topical Vapocoolant to Reduce Pain With Nexplanon Insertion: A Randomized Controlled Trial

The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

This study will be for patients in the office having a Nexplanon (etonogestrel implant) insertion. The doctor in clinic will evaluate if a patient meets eligibility criteria for this study. If the patient meets eligibility criteria, the doctor will inform the patient of the study and the potential risks. If patients elect to participate, a research coordinator will obtain written informed consent. The patient will be randomized (patient is blinded) to receive either Pain Ease vapocoolant spray or placebo (normal saline) spray. They will receive the spray just before lidocaine injection during the Nexplanon insertion procedure. The purpose of the study is to see if Pain Ease vapocoolant spray reduces patient pain during lidocaine injection for Nexplanon insertion.

Inclusion Criteria:

• At least 14 years or older
• Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
• English speaking
• Able and willing to sign the informed consent form and agree to terms of the study

Exclusion Criteria:

• Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
• Known previous exposure to vapocoolant spray
• Nexplanon removal and reinsertion same day during visit in the same arm
• Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
• Unable to provide written, informed consent in English